利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

818 条记录 (耗时 0.047 秒)

    Substituted pyran derivatives
    3.
    发明授权
    Substituted pyran derivatives 有权
    取代的吡喃衍生物

    公开(公告)号：US09458124B2

    公开(公告)日：2016-10-04

    申请号：US14173997

    申请日：2014-02-06

    申请人： Wayne State University

    发明人： Aloke K. Dutta

    IPC分类号： C07D407/00 ,  C07D315/00 ,  C07D309/14 ,  C07D407/12 ,  C07D413/12 ,  C07D405/12 ,  C07D417/12

    CPC分类号： C07D309/14 ,  C07D405/12 ,  C07D407/12 ,  C07D413/12 ,  C07D417/12

    摘要： Certain 3,6-disubstituted and 2,4,5-trisubstituted pyran derivatives that exhibit potent activity on monoamine transport systems are provided. The 3,6 and 2,4,5 pyrans are useful in probing the effects of their binding to monoamine transporter systems and the corresponding relationships to various afflictions affecting the CNS, or as a treatment for various CNS-related disorders in which the monoamine transport and related systems are implicated.

    摘要翻译： 提供了对单胺转运体系表现出有效活性的某些3,6-二取代和2,4,5-三取代的吡喃衍生物。 3,6和2,4,5 pyrans可用于探测其结合单胺转运蛋白系统的作用以及与影响CNS的各种疾病的相应关系，或作为治疗各种CNS相关疾病的治疗，其中单胺转运 并涉及相关系统。

    Compound having 2-fluorophenyloxymethane structure
    4.
    发明授权
    Compound having 2-fluorophenyloxymethane structure 有权
    具有2-氟苯氧基甲烷结构的化合物

    公开(公告)号：US09181484B2

    公开(公告)日：2015-11-10

    申请号：US14353417

    申请日：2013-04-24

    申请人： DIC CORPORATION

    发明人： Kenta Tojo ,  Tetsuo Kusumoto ,  Masashi Osawa ,  Masakazu Kaneoya ,  Kiyofumi Takeuchi

    IPC分类号： C07D315/00 ,  C09K19/52 ,  C09K19/30 ,  C09K19/12 ,  C09K19/00 ,  C09K19/34 ,  C09K19/20 ,  C09K19/32 ,  C09K19/04

    CPC分类号： C09K19/3402 ,  C09K19/20 ,  C09K19/3066 ,  C09K19/322 ,  C09K2019/0466 ,  C09K2019/3422

    摘要： There is provided a compound having a good miscibility with another liquid crystal compound and having a combination of a low viscosity (η), high storage stability, and high T−i even after being used to produce a liquid crystal composition. In particular, it is a compound having a 2-fluorophenyloxymethane structure is provided. Since the compound having a 2-fluorophenyloxymethane structure is highly miscible with another liquid crystal compound, using the compound having a 2-fluorophenyloxymethane structure as a component of a liquid crystal composition enables a production of a liquid crystal composition which exhibits a liquid crystal phase at low viscosity and in a wide temperature range and which has a high storage stability and enables production of a liquid crystal display device which responds fast and which has excellent display characteristics.

    摘要翻译： 即使在制造液晶组合物之后，也提供了与另一种液晶化合物具有良好的混溶性并且具有低粘度（高），高储存稳定性和高T-i组合的化合物。 特别是提供具有2-氟苯氧基甲烷结构的化合物。 由于具有2-氟苯氧基甲烷结构的化合物与另一种液晶化合物高度混溶，因此使用具有2-氟苯氧基甲烷结构的化合物作为液晶组合物的组分使得能够制备在液晶组合物中显示液晶相的液晶组合物 低粘度和宽的温度范围，并且具有高的储存稳定性，并且能够制造快速响应并且具有优异的显示特性的液晶显示装置。

    Mesogenic stabilizers
    5.
    发明授权
    Mesogenic stabilizers 有权
    介晶稳定剂

    公开(公告)号：US08623238B2

    公开(公告)日：2014-01-07

    申请号：US13204861

    申请日：2011-08-08

    申请人： Ruisong Xu ,  Xiao-Man Dai ,  Anil Kumar ,  Meng He ,  Chenguang Li ,  Rachael L. Yoest

    发明人： Ruisong Xu ,  Xiao-Man Dai ,  Anil Kumar ,  Meng He ,  Chenguang Li ,  Rachael L. Yoest

    IPC分类号： C09K19/52 ,  C09K19/06 ,  C09K19/34 ,  C09K19/32 ,  C09K19/00 ,  C09K19/08 ,  C07D211/00 ,  C07C69/76 ,  C07D315/00

    CPC分类号： C09K19/3483 ,  C07D211/46 ,  C09K19/54 ,  C09K2019/0448

    摘要： The present invention relates to compounds represented by the following Formula Ic, in which R2-R6 can each independently be selected from hydrogen or hydrocarbyl (e.g., methyl); L1 and L4 are each independently a divalent linking group, such as a bond or —OC(O)—R8—C(O)O—, where R8 can be divalent hydrocarbyl (e.g., —CH2CH2—); each L2 and each L5 each independently represent a flexible segment, such as divalent linear or branched C1-C25 alkyl; each L3 and each L6 each independently represent a rigid segment including, for example, optionally substituted phenylen-1,4-diyl groups; t and s are each independently from 1 to 4; m and p are each independently from 0 to 4 for each t, provided that the sum of m and p is at least 1 for each t; q and r are each independently from 0 to 4 for each s, provided that the sum of q and r is at least 1 for each s; and E1 and E2 can each independently be hydrogen or hydrocarbyl. The present invention also relates to compositions, such as liquid crystal compositions, and articles, such as optical elements, that include the compound represented by Formula Ic.

    摘要翻译： 本发明涉及由下式Ic表示的化合物，其中R 2 -R 6各自独立地选自氢或烃基（例如甲基）; L 1和L 4各自独立地是二价连接基团，例如键或-OC（O）-R 8 -C（O）O-，其中R 8可以是二价烃基（例如-CH 2 CH 2 - ）。 每个L 2和每个L 5各自独立地表示柔性链段，例如二价直链或支链C 1 -C 25烷基; 每个L3和每个L6各自独立地表示包括例如任选取代的苯基-1,4-二基的刚性链段; t和s各自独立地为1至4; 对于每个t，m和p各自独立地为0至4，条件是对于每个t，m和p之和至少为1; q和r各自各自为0至4，条件是每个s的q和r之和至少为1; E1和E2各自独立地为氢或烃基。 本发明还涉及包含式Ic表示的化合物的组合物，例如液晶组合物和诸如光学元件的制品。

    Isoxazol-3(2H)-one analogs as therapeutic agents
    8.
    发明授权
    Isoxazol-3(2H)-one analogs as therapeutic agents 有权
    异恶唑-3（2H） - 酮类似物作为治疗剂

    公开(公告)号：US08415378B2

    公开(公告)日：2013-04-09

    申请号：US12755010

    申请日：2010-04-06

    申请人： Jonas Boström ,  Leifeng Cheng ,  Tomas Fex ,  Michael Karle ,  Daniel Pettersen ,  Peter Schell

    发明人： Jonas Boström ,  Leifeng Cheng ,  Tomas Fex ,  Michael Karle ,  Daniel Pettersen ,  Peter Schell

    IPC分类号： A01N43/40 ,  A01N43/80 ,  A61K31/445 ,  A61K31/42 ,  C07D401/00 ,  C07D405/00 ,  C07D409/00 ,  C07D411/00 ,  C07D413/00 ,  C07D417/00 ,  C07D419/00 ,  C07D421/00 ,  C07D261/00 ,  C07D307/02 ,  C07D315/00 ,  C07D407/00

    CPC分类号： C07D413/04

    摘要： or a pharmaceutically suitable salt thereof, wherein, R1 and R2 independently are hydrogen, deuterium, aryl, hetero aryl, C1-C8 alkyl, optionally being substituted with one or more substituents independently being R3, R3 is an aryl, hetero aryl, fluorine(s), a C1-C6 alkyl containing one or more fluorine, a C1-C6 alkyl containing one or more deuterium, a C1-C6 alkyl containing hydroxy, the aryl and heteroaryl optionally being substituted with one or more halogen, a fluorinated alkoxy, a fluorinated alkyl, a sulfonyl, one or more deuterium, a C1-6 alkyl, a C1-6 alkoxy, a nitrile, or R3 is a C1-6 alkyl optionally substituted with one or more of the following groups: COOR4, OCOR4, CONR5R6, NR5COR6, OR4; wherein, R4 is a C1-10 alkyl optionally substituted with one or more fluorine, deuterium, alkoxy, arylcarboxylate, alkyl carboxylate; R5 and R6 are independently selected from hydrogen, alkyl or they may together form a 4-8 membered carbon ring; or R1 and R2 form a 3-10 membered carbon ring optionally comprising O or N and optionally substituted with a C1-10 alkyl or aryl, hetero aryl optionally substituted with R3.

    摘要翻译： 或其药学上合适的盐，其中R 1和R 2独立地是氢，氘，芳基，杂芳基，任选被一个或多个取代基独立地被R 3取代的C 1 -C 8烷基，R 3是芳基，杂芳基，氟（ 含有一个或多个氟的C 1 -C 6烷基，含有一个或多个氘的C 1 -C 6烷基，含羟基的C 1 -C 6烷基，任选被一个或多个卤素取代的芳基和杂芳基，氟化烷氧基， 氟化烷基，磺酰基，一个或多个氘，C 1-6烷基，C 1-6烷氧基，腈或R 3是任选被一个或多个下列基团取代的C 1-6烷基：COOR 4，OCOR 4， CONR5R6，NR5COR6，OR4; 其中，R4为任选被一个或多个氟，氘，烷氧基，芳基羧酸酯，羧酸烷基酯取代的C 1-10烷基; R 5和R 6独立地选自氢，烷基或它们可以一起形成4-8元碳环; 或R 1和R 2形成任选地包含O或N并任选被C 1-10烷基或芳基取代的3-10元碳环，任选被R 3取代的杂芳基。